European Companies Search Engine
EU funding (€3,301,990): Early detection of cervical cancer in hard-to-reach populations of women through portable and point-of-care HPV testing Hor 1 Jan 2019 EU Research and Innovation programme "Horizon"
Text
Early detection of cervical cancer in hard-to-reach populations of women through portable and point-of-care HPV testing
Cervical cancer is the 4th most common cancer in women worlThe ELEVATE project sets a multidisciplinary team comprising manufactures and experts from Europe and the Community of Latin American and Caribbean States, to improve the global adequacy and coverage of cervical cancer screening, particularly to specific populations of women that by not being regularly screened (hard-to-reach populations) are at higher-risk to develop cervical cancer. Although Cervical cancer is still the fourth most common cancer in women worldwide, with up to 85% of the burden occurring in developing countries, preventive vaccination against human papillomavirus and early detection of precancer in screening programs has shown to be successful in reducing cancer incidence and mortality.1–3 However, different challenges hamper a global implementation of such programs and are in the base of women’s non-attendance to screening. This highlights the lack of reflection of ethnic, cultural and resource differences from different populations in current cervical cancer screening. In ELEVATE it is proposed to conduct social science investigations to identify hard-to-reach women in Belgium, Brazil, Ecuador and Portugal, to address their barriers to screening and to design strategies to make primary screening more accessible to them, and therefore, contribute to reduce the global burden of cervical cancer. This will be complemented with fundamental and technological research to develop an efficient and marketable test for the combined genomic and proteomic detection of high-risk HPV infections in Belgium and Ecuador. The test will be made portable, low-cost, compatible with self-sampling, point-of-care and generate rapid and easy-to-understand results, without relying on electrical outlets or trained health personnel. Integrant part of the proposal is also to infer and disseminate the societal, economic implications of the developed strategies using a hard-to-reach community-based participatory research.
Funded Companies:
| Company name | Funding amount |
| Consorcio DE Investigacion Sobre VIH Sida TB Cisidat | €0.00 |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | €214,578 |
| Fundacao PIO XII | €0.00 |
| Labman Automation Ltd. | €395,420 |
| Microliquid SL | €170,355 |
| Universidad DE Cuenca | €259,900 |
| Universidade Nova de Lisboa | €419,850 |
| Universitat Rovira i Virgili | €341,803 |
| Universiteit Gent | €1,500,085 |
Source: https://cordis.europa.eu/project/id/825747
The filing refers to a past date, and does not necessarily reflect the current state.